Download PDF
CC BY 4.0 · Arq Neuropsiquiatr 2023; 81(10): 883-890
DOI: 10.1055/s-0043-1772831
Original Article

Acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome: prevalence, main characteristics, and outcomes in a Brazilian center

Síndrome inflamatória de reconstituição imune da leucoencefalopatia multifocal progressiva associada à síndrome da imunodeficiência adquirida: prevalência, principais características e desfecho em um hospital brasileiro
Monize Nascimento Santana 
1   Instituto de Infectologia Emílio Ribas, Departamento de Infectologia, São Paulo SP, Brazil.
,
Raphaela Ferrari 
1   Instituto de Infectologia Emílio Ribas, Departamento de Infectologia, São Paulo SP, Brazil.
,
Arthur Cassa Macedo 
2   McGill University, Department of Neurology and Neurosurgery, Montreal QC, Canada.
,
Rosa Maria Nascimento Marcusso 
3   Instituto de Infectologia Emílio Ribas, Departamento de Neurologia, São Paulo SP, Brazil.
,
Ruan de Andrade Fernandes 
1   Instituto de Infectologia Emílio Ribas, Departamento de Infectologia, São Paulo SP, Brazil.
,
José Ernesto Vidal 
3   Instituto de Infectologia Emílio Ribas, Departamento de Neurologia, São Paulo SP, Brazil.
4   Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Moléstias Infecciosas e Parasitárias, São Paulo SP, Brazil.
5   Universidade de São Paulo, Faculdade de Medicina, Laboratório de Investigação Médica (LIM 49), São Paulo SP, Brazil.
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background Progressive multifocal leukoencephalopathy (PML) - immune reconstitution inflammatory syndrome (IRIS) in people living with HIV/AIDS (PLWHA) has been rarely described in low- and middle-income countries.

Objective To describe the prevalence of PML-IRIS among PLWHA with PML and its main features in a tertiary hospital in Brazil.

Methods We performed a retrospective cohort study. We included PLWHA with PML-IRIS patients admitted at Instituto de Infectologia Emílio Ribas, São Paulo, Brazil, between 2011 and 2021. We retrieved information on neurological manifestations, neuroimaging findings, treatments, and outcomes.

Results We identified 11 (11.8%) PML-IRIS cases among 93 patients with definite PML. Eight (73%) cases were men and had a median (IQR) age of 41 (27–50) years. Seven (63.6%) patients developed unmasking PML-IRIS and 4 (36.4%) had paradoxical PML-IRIS. The median (IQR) time from initiation of combined antiretroviral therapy (cART) to IRIS diagnosis was 49 (30–70) days. Ten (90.9%) patients received corticosteroids. There were 4 (36%) in-hospital deaths and 3 were associated with hospital-acquired pneumonia. Among the 7 (64%) patients who survived, 5 (71.5%) had sequelae at discharge. One year after the PML-IRIS diagnosis, 6 (54.5%) patients were alive.

Conclusion The prevalence of PML-IRIS was 11.8%. Most patients had unmasking PML-IRIS. In-hospital mortality and morbidity were high. One-year survival was similar to that described in some high-income countries.

Resumo

Antecedentes A síndrome inflamatória de reconstituição imune (SIRI) da leucoencefalopatia multifocal progressiva (LEMP) em pessoas vivendo com HIV/Aids (PVHA) foi raramente descrita em países de baixa e média renda.

Objetivo Descrever a prevalência da SIRI-LEMP- em PVHA com LEMP e suas principais características em um hospital no Brasil.

Métodos Foi realizado um estudo de coorte retrospectivo. Incluímos PVHA com SIRI-LEMP admitidos no Instituto de Infectologia Emílio Ribas, São Paulo, Brasil, entre 2011 e 2021. Recuperamos informações sobre manifestações neurológicas, neuroimagem, tratamento e desfecho.

Resultados Identificamos 11 (11,8%) casos de SIRI-LEMP entre 93 pacientes com LEMP definitiva. Oito (73%) casos eram homens e a mediana de idade (amplitude interquartile - AIQ) foi de 41 (27–50) anos. Sete (63,6%) pacientes desenvolveram SIRI-LEMP “desmascarada” e 4 (36,4%) casos apresentaram SIRI-LEMP “paradoxal”. A mediana de tempo (AIQ) desde o início da terapia antirretroviral combinada (cART) até o diagnóstico de SIRI foi de 49 (30–70) dias. Dez (90,9%) pacientes receberam corticoide. Houve 4 (36%) óbitos intra-hospitalares e 3 foram associados à pneumonia hospitalar. Dos 7 (64%) pacientes que sobreviveram, 5 (71,5%) ficaram com sequelas na alta. Um ano após o diagnóstico de SIRI-LEMP, 6 (54,5%) pacientes estavam vivos.

Conclusão A prevalência de SIRI-LEMP foi de 11,8%. A maioria dos pacientes apresentava SIRI-LEMP “desmascarada”. A mortalidade e morbidade hospitalar foram altas. A sobrevida em 1 ano foi semelhante à descrita em alguns países de alta renda.

Keywords

Leukoencephalopathy, Progressive Multifocal - Immune Reconstitution Inflammatory Syndrome - Epidemiology - HIV - Brazil

Palavras-chave

Leucoencefalopatia Multifocal Progressiva - Síndrome Inflamatória da Reconstituição Imune - Epidemiologia - HIV - Brasil

Author's Contributions

MNS: conceptualization, data curation, formal analysis, investigation, methodology, resources, software, writing review, and editing; RF: data curation, investigation, writing review and editing, software; ACM: writing review and editing; RMNM: data curation, formal analysis, writing review and editing, software; RAF: conceptualization, data curation, investigation, writing review and editing, software; JEV: conceptualization, formal analysis, methodology, project administration, resources, supervision, validation, writing-original draft, writing review, and editing.




Publication History

Received: 10 March 2023

Accepted: 07 June 2023

Article published online:
29 October 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Major EO. History and current concepts in the pathogenesis of PML. Cleve Clin J Med 2011; 78 (Suppl. 02) S3-S7
    CrossrefPubMedGoogle Scholar
  • 2 Ferenczy MW, Marshall LJ, Nelson CD. et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012; 25 (03) 471-506
    CrossrefPubMedGoogle Scholar
  • 3 Åström KE, Mancall EL, Richardson Jr EP. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81 (01) 93-111
    PubMedGoogle Scholar
  • 4 Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1 (7712) 1257-1260
    CrossrefPubMedGoogle Scholar
  • 5 Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin 1984; 2 (02) 299-313
    CrossrefPubMedGoogle Scholar
  • 6 Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9 (04) 425-437
    CrossrefPubMedGoogle Scholar
  • 7 Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4 (01) 59-68
    CrossrefPubMedGoogle Scholar
  • 8 d'Arminio Monforte A, Cinque P, Mocroft A. et al; EuroSIDA Study Group. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55 (03) 320-328
    CrossrefPubMedGoogle Scholar
  • 9 Wyen C, Hoffmann C, Schmeisser N. et al. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004; 37 (02) 1263-1268
    CrossrefPubMedGoogle Scholar
  • 10 Antinori A, Cingolani A, Lorenzini P. et al; Italian Registry Investigative Neuro AIDS Study Group. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9 (Suppl. 01) 47-53
    CrossrefPubMedGoogle Scholar
  • 11 Engsig FN, Hansen AB, Omland LH. et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199 (01) 77-83
    CrossrefPubMedGoogle Scholar
  • 12 Cinque P, Bossolasco S, Brambilla AM. et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9 (Suppl. 01) 73-80
    CrossrefPubMedGoogle Scholar
  • 13 Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57 (02) 167-170
    CrossrefPubMedGoogle Scholar
  • 14 Fournier A, Martin-Blondel G, Lechapt-Zalcman E. et al. Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review. Front Immunol 2017; 8: 577
    CrossrefPubMedGoogle Scholar
  • 15 Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10 (04) 251-261
    CrossrefPubMedGoogle Scholar
  • 16 Vidal JE, Penalva de Oliveira AC, Fink MC, Pannuti CS, Trujillo JR. Aids-related progressive multifocal leukoencephalopathy: a retrospective study in a referral center in São Paulo, Brazil. Rev Inst Med Trop São Paulo 2008; 50 (04) 209-212
    CrossrefPubMedGoogle Scholar
  • 17 Guevara-Silva EA, Ramírez-Crescencio MA, Soto-Hernández JL, Cárdenas G. Central nervous system immune reconstitution inflammatory syndrome in AIDS: experience of a Mexican neurological centre. Clin Neurol Neurosurg 2012; 114 (07) 852-861
    CrossrefPubMedGoogle Scholar
  • 18 Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72 (17) 1458-1464
    CrossrefPubMedGoogle Scholar
  • 19 Berger JR, Aksamit AJ, Clifford DB. et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80 (15) 1430-1438
    CrossrefPubMedGoogle Scholar
  • 20 Sainz-de-la-Maza S, Casado JL, Pérez-Elías MJ. et al. Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy. Eur J Neurol 2016; 23 (05) 919-925
    CrossrefPubMedGoogle Scholar
  • 21 Walker NF, Scriven J, Meintjes G, Wilkinson RJ. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl) 2015; 7: 49-64
    PubMedGoogle Scholar
  • 22 Bahr N, Boulware DR, Marais S, Scriven J, Wilkinson RJ, Meintjes G. Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep 2013; 15 (06) 583-593
    CrossrefPubMedGoogle Scholar
  • 23 Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 2021; 17 (01) 37-51
    CrossrefPubMedGoogle Scholar
  • 24 Shelburne III SA, Hamill RJ, Rodriguez-Barradas MC. et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81 (03) 213-227
    CrossrefPubMedGoogle Scholar
  • 25 French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18 (12) 1615-1627
    CrossrefPubMedGoogle Scholar
  • 26 Riedel DJ, Pardo CA, McArthur J, Nath A. Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol 2006; 2 (10) 557-565
    CrossrefPubMedGoogle Scholar
  • 27 Breton G, Duval X, Estellat C. et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39 (11) 1709-1712
    CrossrefPubMedGoogle Scholar
  • 28 Shelburne SA, Visnegarwala F, Darcourt J. et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19 (04) 399-406
    CrossrefPubMedGoogle Scholar
  • 29 Mateen FJ, Nath A. Central nervous system-immune reconstitution inflammatory syndrome in resource-limited settings: current burden and future needs. AIDS 2012; 26 (15) 1851-1855
    CrossrefPubMedGoogle Scholar
  • 30 Navis A, Siddiqi O, Chishimba L, Zimba S, Morgello S, Birbeck GL. Immune reconstitution inflammatory syndrome in the central nervous system: Limitations for diagnosis in resource limited settings. J Neurol Sci 2020; 416: 117042
    CrossrefPubMedGoogle Scholar
  • 31 Piza F, Fink MC, Nogueira GS, Pannuti CS, Oliveira AC, Vidal JE. JC virus-associated central nervous system diseases in HIV-infected patients in Brazil: clinical presentations, associated factors with mortality and outcome. Braz J Infect Dis 2012; 16 (02) 153-156
    CrossrefPubMedGoogle Scholar
  • 32 Lima MA, Silva MTT, Afonso LA, Vaz BJP. Post-cART progressive multifocal leukoencephalopathy era in a Brazilian center. J Neurol Sci 2017; 381: 321-324
    CrossrefPubMedGoogle Scholar
  • 33 Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43 (08) 4175-4177
    CrossrefPubMedGoogle Scholar
  • 34 Bowen L, Nath A, Smith B. CNS immune reconstitution inflammatory syndrome. Handb Clin Neurol 2018; 152: 167-176
    CrossrefPubMedGoogle Scholar
  • 35 Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?. J Neurovirol 2003; 9 (Suppl. 01) 25-31
    CrossrefPubMedGoogle Scholar
  • 36 Berger JR. Steroids for PML-IRIS: a double-edged sword?. Neurology 2009; 72 (17) 1454-1455
    CrossrefPubMedGoogle Scholar
  • 37 Tassie JM, Gasnault J, Bentata M. et al; Clinical Epidemiology Group. French Hospital Database on HIV. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. AIDS 1999; 13 (14) 1881-1887
    CrossrefPubMedGoogle Scholar
  • 38 Grabar S, Lanoy E, Allavena C. et al; Clinical Epidemiology Group of the French Hospital Database on HIV. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9 (04) 246-256
    CrossrefPubMedGoogle Scholar
  • 39 Khanna N, Elzi L, Mueller NJ. et al; Swiss HIV Cohort Study. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48 (10) 1459-1466
    CrossrefPubMedGoogle Scholar
  • 40 Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009; 9 (10) 625-636
    CrossrefPubMedGoogle Scholar
  • 41 Lanoy E, Guiguet M, Bentata M. et al; FHDH-ANRS CO4. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology 2011; 76 (07) 644-651
    CrossrefPubMedGoogle Scholar